Royalty Pharma plc (RPRX) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
110 EAST 59TH STREET NEW YORK, NY 10022 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in millions)
| 9/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 495 | 1,736 | 2,189 | 2,062 | |||
| Cash and cash equivalents | 477 | 1,711 | 1,541 | 1,009 | |||
| Short-term investments | 18 | 26 | 648 | 1,053 | |||
| Receivables | 738 | 691 | 614 | 587 | |||
| Other current assets | 4 | 91 | 7 | 9 | |||
| Other undisclosed current assets | 37 | 37 | 68 | 39 | |||
| Total current assets: | 1,274 | 2,555 | 2,878 | 2,697 | |||
| Noncurrent Assets | |||||||
| Long-term investments and receivables | 15,101 | 14,229 | 14,628 | 12,967 | |||
| Long-term investments | 1,012 | 736 | 910 | 599 | |||
| Accounts and financing receivable, after allowance for credit loss | 14,089 | 13,493 | 13,718 | 12,368 | |||
| Intangible assets, net (including goodwill) | 6 | 29 | |||||
| Intangible assets, net (excluding goodwill) | 6 | 29 | |||||
| Derivative instruments and hedges | 5 | ||||||
| Other noncurrent assets | 7 | 30 | 4 | 23 | |||
| Other undisclosed noncurrent assets | 299 | ||||||
| Total noncurrent assets: | 15,108 | 14,259 | 14,638 | 13,323 | |||
| TOTAL ASSETS: | 16,382 | 16,813 | 17,516 | 16,020 | |||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities, including: | 15 | 8 | 6 | 11 | |||
| Interest and dividends payable | ✕ | ✕ | ✕ | 58 | 42 | ||
| Accrued liabilities | 52 | 54 | |||||
| Other undisclosed accounts payable and accrued liabilities | (37) | (46) | (52) | (31) | |||
| Debt | 998 | ||||||
| Other liabilities | 11 | 12 | |||||
| Due to related parties | ✕ | ✕ | 95 | 108 | 126 | ||
| Other undisclosed current liabilities | 135 | 54 | 58 | 171 | |||
| Total current liabilities: | 161 | 1,167 | 171 | 308 | |||
| Noncurrent Liabilities | |||||||
| Long-term debt and lease obligation | 6,135 | 6,119 | 7,096 | 5,817 | |||
| Long-term debt, excluding current maturities | 6,135 | 6,119 | 7,096 | 5,817 | |||
| Liabilities, other than long-term debt | 1 | 3 | |||||
| Other liabilities | 1 | 3 | |||||
| Total noncurrent liabilities: | 6,136 | 6,121 | 7,096 | 5,817 | |||
| Total liabilities: | 6,298 | 7,288 | 7,267 | 6,124 | |||
| Equity | |||||||
| Equity, attributable to parent | 6,526 | 5,628 | 5,776 | 4,819 | |||
| Treasury stock, value | (3) | (3) | (3) | (2) | |||
| Additional paid in capital | 4,011 | 3,666 | 3,508 | 2,866 | |||
| Accumulated other comprehensive income | 16 | 34 | |||||
| Retained earnings | 2,518 | 1,965 | 2,255 | 1,921 | |||
| Equity, attributable to noncontrolling interest | 3,558 | 3,897 | 4,472 | 5,077 | |||
| Other undisclosed equity | 0 | 0 | 0 | 0 | |||
| Total equity: | 10,084 | 9,525 | 10,249 | 9,896 | |||
| TOTAL LIABILITIES AND EQUITY: | 16,382 | 16,813 | 17,516 | 16,020 | |||
Income Statement (P&L) ($ in millions)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|---|
| Revenues | 2,355 | 2,237 | 2,289 | 2,122 | ||
| Cost of revenue | (561) | (904) | (453) | (231) | ||
| Provision for loan, lease, and other losses | (561) | (710) | (453) | (231) | ||
| Gross profit: | 1,794 | 1,333 | 1,837 | 1,892 | ||
| Operating expenses | (302) | (1,026) | (406) | (296) | ||
| Other undisclosed operating income | ||||||
| Operating income: | 1,492 | 307 | 1,431 | 1,595 | ||
| Nonoperating income (expense) | 208 | (77) | (190) | 107 | ||
| Investment income, nonoperating | 70 | 175 | 32 | (14) | ||
| Other nonoperating expense | (22) | (15) | (6) | (33) | ||
| Interest and debt expense | (187) | (0) | (0) | (30) | ||
| Income from continuing operations before equity method investments, income taxes: | 1,513 | 230 | 1,241 | 1,672 | ||
| Other undisclosed income from continuing operations before income taxes | 187 | 0 | 0 | 30 | ||
| Income from continuing operations: | 1,700 | 230 | 1,241 | 1,702 | ||
| Income before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | 1,241 | 1,702 | |
| Net income: | 1,700 | 230 | 1,241 | 1,702 | ||
| Net loss attributable to noncontrolling interest | (727) | |||||
| Other undisclosed net loss attributable to parent | (565) | (187) | (621) | |||
| Net income attributable to parent: | 1,135 | 43 | 620 | 975 | ||
| Other undisclosed net loss available to common stockholders, basic | (480) | |||||
| Net income available to common stockholders, basic: | 1,135 | 43 | 620 | 495 | ||
| Dilutive securities, effect on basic earnings per share | 393 | |||||
| Net income available to common stockholders, diluted: | 1,528 | 43 | 620 | 495 | ||
Comprehensive Income ($ in millions)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|---|
| Net income: | 1,700 | 230 | 1,241 | 1,702 | ||
| Other comprehensive income (loss) | (29) | (39) | 67 | |||
| Other undisclosed comprehensive loss | (727) | |||||
| Comprehensive income: | 1,700 | 201 | 1,202 | 1,042 | ||
| Comprehensive loss, net of tax, attributable to noncontrolling interest | (565) | (175) | (604) | (13) | ||
| Comprehensive income, net of tax, attributable to parent: | 1,135 | 25 | 598 | 1,029 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.